Recent articles

Erlotinib

Erlotinib (Tarceva®) was the first EGFR tyrokinase inhibitor to be authorized for the treatment of non-small-cell lung carcinoma (NSCLC). It enabled outpatient treatment, and has a more favourable ...

In short Read article


An app as a medical device?

The use of apps as medical devices can be advantageous for both patients and care providers, on condition that these products are thoroughly investigated and conform to the requirements for medica ...

In short Read article